RxDoctor Payments Data

Jonathan Gandhi, MD

Clinical Cardiac Electrophysiology · Nashville, TNNPI 1568806784

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (55.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 76.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $17,049 and has fallen 87.8% since, to $2,078 in 2025.

$36,024in general payments, 2019–2025

Across 409 payments — averaging $88.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$28K
  • Medtronic$4K
  • Abbott$3K
  • Biotronik Inc.$452
  • Johnson & Johnson$191
  • Biosense Webster, Inc.$189
  • plus $658 from 11 others

What the payments were for

  • Grants$20,00056%
  • Travel & lodging$2,1776%
  • Food & beverage$13,41537%
  • Education$4321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,024 in reported general payments places this provider in the 75th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

See all clinical cardiac electrophysiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$253,331
Medicare patients
485
Services billed
2,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$400,559
XareltoRivaroxaban44$48,372
Amiodarone Hcl184$5,459
Metoprolol Succinate284$3,893
Flecainide Acetate90$3,260
Propafenone Hcl ErPropafenone Hcl16$2,307
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$556
ClopidogrelClopidogrel Bisulfate39$507
SotalolSotalol Hcl27$292
Metoprolol Tartrate21$152
Carvedilol18$130
Amlodipine Besylate11$33

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$400,559465 claims
Johnson & JohnsonXarelto$191$48,37244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

Other clinical cardiac electrophysiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →